Study to Evaluate the Safety, Tolerability, and Activity of CM-101 in Patients With Systemic Sclerosis

Summary

This study is designed to assess the safety and tolerability of the anti-human CCL24 monoclonal antibody CM-101 in adult patients with systemic sclerosis (SSc). Approximately 45 patients at approximately 40 sites will be randomized in a 2:1 ratio to receive either 10 mg/kg CM-101 or placebo.

Timeline

Start

2026-09

Primary completion

2028-06

Completion

2028-12

Outcome

Outcome not reported

Stopped (Business): “pending financial resources”

Drugs

Indications